New drug combo shows promise for tough gynecological cancers
NCT ID NCT07448922
First seen Mar 27, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study tests an experimental drug called SKB518, given alone or with chemotherapy, in 280 people with advanced ovarian, cervical, or endometrial cancers. The goal is to see if the drug can shrink tumors or slow cancer growth. Researchers will also monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB518 (an experimental drug), carboplatin (chemotherapy), and bevacizumab (targeted therapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced gynecological cancers that are hard to treat.
What could go wrong
This is an early Phase 2 trial, so the drug may not work as hoped or could have unexpected side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.